JP2018514189A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018514189A5 JP2018514189A5 JP2017546801A JP2017546801A JP2018514189A5 JP 2018514189 A5 JP2018514189 A5 JP 2018514189A5 JP 2017546801 A JP2017546801 A JP 2017546801A JP 2017546801 A JP2017546801 A JP 2017546801A JP 2018514189 A5 JP2018514189 A5 JP 2018514189A5
- Authority
- JP
- Japan
- Prior art keywords
- sepsis
- subject
- biomarker
- patient
- kiaa1370
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000090 biomarker Substances 0.000 claims 36
- 206010040047 Sepsis Diseases 0.000 claims 32
- 230000014509 gene expression Effects 0.000 claims 24
- 238000000034 method Methods 0.000 claims 21
- 239000000523 sample Substances 0.000 claims 15
- 102100021703 C3a anaphylatoxin chemotactic receptor Human genes 0.000 claims 13
- 108010062802 CD66 antigens Proteins 0.000 claims 13
- 102100024533 Carcinoembryonic antigen-related cell adhesion molecule 1 Human genes 0.000 claims 13
- 101000903742 Homo sapiens Basic leucine zipper transcriptional factor ATF-like Proteins 0.000 claims 13
- 101000896583 Homo sapiens C3a anaphylatoxin chemotactic receptor Proteins 0.000 claims 13
- 101000818425 Homo sapiens Palmitoyltransferase ZDHHC19 Proteins 0.000 claims 13
- 101000911541 Homo sapiens Protein FAM214A Proteins 0.000 claims 13
- 102100021068 Palmitoyltransferase ZDHHC19 Human genes 0.000 claims 13
- 102100026957 Protein FAM214A Human genes 0.000 claims 13
- 102100021398 Transforming growth factor-beta-induced protein ig-h3 Human genes 0.000 claims 13
- 102100040089 X-linked retinitis pigmentosa GTPase regulator-interacting protein 1 Human genes 0.000 claims 13
- 102000039446 nucleic acids Human genes 0.000 claims 13
- 108020004707 nucleic acids Proteins 0.000 claims 13
- 150000007523 nucleic acids Chemical class 0.000 claims 13
- 102100022970 Basic leucine zipper transcriptional factor ATF-like Human genes 0.000 claims 12
- 102100023954 Guanine nucleotide-binding protein subunit alpha-15 Human genes 0.000 claims 12
- 101000904080 Homo sapiens Guanine nucleotide-binding protein subunit alpha-15 Proteins 0.000 claims 12
- 101000633302 Homo sapiens Nicotinamide riboside kinase 1 Proteins 0.000 claims 12
- 101000894525 Homo sapiens Transforming growth factor-beta-induced protein ig-h3 Proteins 0.000 claims 12
- 101001104110 Homo sapiens X-linked retinitis pigmentosa GTPase regulator-interacting protein 1 Proteins 0.000 claims 12
- 102100023198 Mitochondrial carrier homolog 1 Human genes 0.000 claims 12
- 102100029562 Nicotinamide riboside kinase 1 Human genes 0.000 claims 12
- 108010045483 HLA-DPB1 antigen Proteins 0.000 claims 11
- 101000623667 Homo sapiens Mitochondrial carrier homolog 1 Proteins 0.000 claims 11
- 102100031618 HLA class II histocompatibility antigen, DP beta 1 chain Human genes 0.000 claims 10
- 108091034117 Oligonucleotide Proteins 0.000 claims 10
- 108091033319 polynucleotide Proteins 0.000 claims 10
- 102000040430 polynucleotide Human genes 0.000 claims 10
- 239000002157 polynucleotide Substances 0.000 claims 10
- 238000003745 diagnosis Methods 0.000 claims 8
- 239000012472 biological sample Substances 0.000 claims 6
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 238000004458 analytical method Methods 0.000 claims 4
- 238000000338 in vitro Methods 0.000 claims 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 3
- 230000003247 decreasing effect Effects 0.000 claims 3
- 238000002493 microarray Methods 0.000 claims 3
- 238000002560 therapeutic procedure Methods 0.000 claims 3
- 101150111527 HLA-DPB1 gene Proteins 0.000 claims 2
- 238000010240 RT-PCR analysis Methods 0.000 claims 2
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 230000003321 amplification Effects 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 230000000295 complement effect Effects 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 230000002458 infectious effect Effects 0.000 claims 2
- 230000004968 inflammatory condition Effects 0.000 claims 2
- 210000001616 monocyte Anatomy 0.000 claims 2
- 210000000440 neutrophil Anatomy 0.000 claims 2
- 238000003199 nucleic acid amplification method Methods 0.000 claims 2
- 210000002381 plasma Anatomy 0.000 claims 2
- 238000003752 polymerase chain reaction Methods 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 101100458431 Homo sapiens MTCH1 gene Proteins 0.000 claims 1
- 101150089537 MTCH1 gene Proteins 0.000 claims 1
- 101100229631 Mus musculus Gna15 gene Proteins 0.000 claims 1
- 238000000636 Northern blotting Methods 0.000 claims 1
- 101150093838 RPGRIP1 gene Proteins 0.000 claims 1
- 101150040304 TGFBI gene Proteins 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000007418 data mining Methods 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 230000002542 deteriorative effect Effects 0.000 claims 1
- 238000005516 engineering process Methods 0.000 claims 1
- 238000010195 expression analysis Methods 0.000 claims 1
- 239000007850 fluorescent dye Substances 0.000 claims 1
- 238000009396 hybridization Methods 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 230000000155 isotopic effect Effects 0.000 claims 1
- 238000010208 microarray analysis Methods 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 235000002020 sage Nutrition 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 230000008736 traumatic injury Effects 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021203291A JP2022058359A (ja) | 2015-03-12 | 2021-12-15 | 敗血症の診断法 |
| JP2023107866A JP2023138990A (ja) | 2015-03-12 | 2023-06-30 | 敗血症の診断法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562132293P | 2015-03-12 | 2015-03-12 | |
| US62/132,293 | 2015-03-12 | ||
| PCT/US2016/022233 WO2016145426A1 (en) | 2015-03-12 | 2016-03-12 | Methods for diagnosis of sepsis |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021203291A Division JP2022058359A (ja) | 2015-03-12 | 2021-12-15 | 敗血症の診断法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018514189A JP2018514189A (ja) | 2018-06-07 |
| JP2018514189A5 true JP2018514189A5 (enExample) | 2019-04-18 |
| JP6995622B2 JP6995622B2 (ja) | 2022-01-14 |
Family
ID=56878909
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017546801A Active JP6995622B2 (ja) | 2015-03-12 | 2016-03-12 | 敗血症の診断法 |
| JP2021203291A Pending JP2022058359A (ja) | 2015-03-12 | 2021-12-15 | 敗血症の診断法 |
| JP2023107866A Pending JP2023138990A (ja) | 2015-03-12 | 2023-06-30 | 敗血症の診断法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021203291A Pending JP2022058359A (ja) | 2015-03-12 | 2021-12-15 | 敗血症の診断法 |
| JP2023107866A Pending JP2023138990A (ja) | 2015-03-12 | 2023-06-30 | 敗血症の診断法 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US10533224B2 (enExample) |
| EP (1) | EP3268499B1 (enExample) |
| JP (3) | JP6995622B2 (enExample) |
| CN (1) | CN107532214B (enExample) |
| AU (2) | AU2016228508A1 (enExample) |
| CA (1) | CA2977422A1 (enExample) |
| IL (3) | IL297699A (enExample) |
| WO (1) | WO2016145426A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015135071A1 (en) | 2014-03-14 | 2015-09-17 | Hancock Robert E W | Diagnostic for sepsis |
| GB201616557D0 (en) * | 2016-09-29 | 2016-11-16 | Secretary Of State For Health The | Assay for distinguishing between sepsis and systemic inflammatory response syndrome |
| US20190354814A1 (en) * | 2017-01-08 | 2019-11-21 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Systems and methods for using supervised learning to predict subject-specific bacteremia outcomes |
| EP3477305A1 (en) | 2017-10-25 | 2019-05-01 | Universität Heidelberg | Delta-like ligand 1 for diagnosing severe infections |
| US10433191B2 (en) * | 2018-01-08 | 2019-10-01 | Cisco Technology, Inc. | Channel management in a virtual access point (VAP) |
| US11538566B2 (en) * | 2018-05-23 | 2022-12-27 | Beckman Coulter, Inc. | Sample analysis with test determination based on identified condition |
| US20210369797A1 (en) * | 2018-10-04 | 2021-12-02 | Western Sydney Local Health District | Bacteriophage treatment and reduction in inflammatory response |
| WO2020096984A1 (en) * | 2018-11-05 | 2020-05-14 | Institute For Systems Biology | Sepsis biomarker panels and methods of use |
| CN113785074A (zh) | 2019-03-25 | 2021-12-10 | 斯坦福大学托管董事会 | 用于诊断细菌感染与病毒感染的特征 |
| US11104946B2 (en) | 2019-04-23 | 2021-08-31 | Inflammatix, Inc. | DNA sequences related to diagnosis and treatment of systemic inflammatory response syndrome |
| CN112391460A (zh) * | 2019-08-19 | 2021-02-23 | 四川生美思达生物科技有限公司 | 用于脓毒症的生物标志物组及脓毒症判断方法和试剂盒 |
| CA3098079C (en) * | 2019-12-13 | 2023-06-20 | Autonomous Medical Devices Inc. | Apparatus and method for point-of-care, rapid, field-deployable diagnostic testing of covid-19, viruses, antibodies and markers |
| KR102281512B1 (ko) * | 2020-03-26 | 2021-07-23 | 경북대학교 산학협력단 | TGFBIp의 아세틸화 수준을 측정하는 제제를 포함하는 염증성 질환 진단용 조성물 |
| JP2023525489A (ja) * | 2020-04-29 | 2023-06-16 | インフラマティックス インコーポレイテッド | ウイルス感染症を有する対象の死亡率リスクの決定 |
| CN111563891B (zh) * | 2020-05-09 | 2023-09-26 | 吾征智能技术(北京)有限公司 | 基于颜色认知的疾病预测系统 |
| FR3112207A1 (fr) * | 2020-07-06 | 2022-01-07 | bioMérieux | Procédé pour déterminer le risque de survenue d’une infection associée aux soins chez un patient |
| FR3112209A1 (fr) * | 2020-07-06 | 2022-01-07 | bioMérieux | Procédé pour déterminer le risque de complication chez un patient |
| FR3112211A1 (fr) * | 2020-07-06 | 2022-01-07 | bioMérieux | Procédé pour déterminer le risque de survenue d’une infection associée aux soins chez un patient |
| CN111721941B (zh) * | 2020-07-17 | 2023-08-25 | 南方科技大学 | 一种用于判断脓毒症感染情况的装置及其应用 |
| WO2022066963A1 (en) * | 2020-09-25 | 2022-03-31 | The Board Of Trustees Of The Leland Stanford Junior University | Method for determining a virally-infected subject's risk of developing severe symptoms |
| JP2024520049A (ja) | 2021-05-25 | 2024-05-21 | ザ ユニヴァーシティ オブ ブリティッシュ コロンビア | 敗血症のエンドタイプおよび／または重症度の診断 |
| WO2023023125A1 (en) * | 2021-08-17 | 2023-02-23 | Predigen, Inc. | Methods for characterizing infections and methods for developing tests for the same |
| CN115295151B (zh) * | 2022-09-01 | 2024-12-27 | 中山大学附属第三医院 | 脓毒症预测系统、预测模型构建方法及系统、试剂盒 |
| CN120809235A (zh) * | 2025-09-04 | 2025-10-17 | 华中科技大学同济医学院附属同济医院 | 一种基于人工智能的多发伤患者脓毒症的早期预警方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004009952B4 (de) * | 2004-03-01 | 2011-06-01 | Sirs-Lab Gmbh | Verfahren zur Erkennung von Sepsis |
| SG119251A1 (en) * | 2004-08-04 | 2006-02-28 | Agency Science Tech & Res | Methods |
| BRPI0609302A2 (pt) * | 2005-04-15 | 2011-10-11 | Becton Dickinson Co | métodos para prever o desenvolvimento de sepse e para diagnosticar sepse em um indivìduo a ser testado, microarranjo, kit para prever o desenvolvimento de sepse em um indivìduo a ser testado, produto de programa de computador, computador, sistema de computador para determinar se um indivìduo é susceptìvel de desenvolver sepse, sinal digital embutido em uma onda portadora, e, interface gráfica de usuário para determinar se um indivìduo é susceptìvel de desenvolver sepse |
| DE102005050933A1 (de) * | 2005-10-21 | 2007-04-26 | Justus-Liebig-Universität Giessen | Erfindung betreffend Expressionsprofile zur Vorhersage von septischen Zuständen |
| EP2643483A4 (en) * | 2010-11-26 | 2014-04-30 | Immunexpress Pty Ltd | DIAGNOSTIC AND / OR SCREENING APPROPRIATIONS AND USES THEREFOR |
| US20150038351A1 (en) | 2012-09-11 | 2015-02-05 | The Regents Of The University Of California | Gene Signatures That Predispose Or Protect Individuals From Low-Dose Radiation Induced Breast Cancer Or Are Associated with Disease-Free Survival |
| WO2014201516A2 (en) * | 2013-06-20 | 2014-12-24 | Immunexpress Pty Ltd | Biomarker identification |
-
2016
- 2016-03-12 EP EP16762690.2A patent/EP3268499B1/en active Active
- 2016-03-12 US US15/526,306 patent/US10533224B2/en active Active
- 2016-03-12 WO PCT/US2016/022233 patent/WO2016145426A1/en not_active Ceased
- 2016-03-12 AU AU2016228508A patent/AU2016228508A1/en not_active Abandoned
- 2016-03-12 JP JP2017546801A patent/JP6995622B2/ja active Active
- 2016-03-12 CN CN201680023601.1A patent/CN107532214B/zh active Active
- 2016-03-12 IL IL297699A patent/IL297699A/en unknown
- 2016-03-12 CA CA2977422A patent/CA2977422A1/en active Pending
-
2017
- 2017-08-30 IL IL254229A patent/IL254229B/en unknown
-
2019
- 2019-11-20 US US16/689,926 patent/US20200131577A1/en not_active Abandoned
-
2021
- 2021-09-30 IL IL286853A patent/IL286853B2/en unknown
- 2021-12-15 JP JP2021203291A patent/JP2022058359A/ja active Pending
-
2022
- 2022-05-18 AU AU2022203348A patent/AU2022203348A1/en not_active Abandoned
-
2023
- 2023-03-08 US US18/180,833 patent/US20230227911A1/en active Pending
- 2023-06-30 JP JP2023107866A patent/JP2023138990A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018514189A5 (enExample) | ||
| JP6681337B2 (ja) | 敗血症の発症を予測するための装置、キット及び方法 | |
| JP2017512304A5 (enExample) | ||
| KR101672531B1 (ko) | 조기 유방암 예후 예측 진단용 유전자 마커 및 이의 용도 | |
| JP6164689B2 (ja) | 乳癌術前化学療法に対する感受性の診断補助方法および判定装置 | |
| JP2020519296A (ja) | 膀胱がん監視のためのｄｎａメチル化および変異分析方法 | |
| US20250137066A1 (en) | Compostions and methods for diagnosing lung cancers using gene expression profiles | |
| TWI682034B (zh) | 用於評估子宮內膜癌的發展風險或診斷子宮內膜癌的方法 | |
| JP6200281B2 (ja) | 甲状腺腫瘍の性状の判別を補助する方法およびその方法に用いるマーカーセット | |
| CN111315897B (zh) | 用于黑素瘤检测的方法 | |
| JP6612509B2 (ja) | 大腸癌の予後診断を補助する方法、記録媒体および判定装置 | |
| US20240229158A1 (en) | Dna methylation biomarkers for hepatocellular carcinoma | |
| JP7199045B2 (ja) | 乳癌の予後に関する情報の取得方法、乳癌の予後の判定装置及びコンピュータプログラム | |
| US20120264633A1 (en) | Methods for detecting thrombocytosis using biomarkers | |
| CN116949161A (zh) | 一组肺结核血清外泌体miRNA标志物及其应用 | |
| WO2022170133A1 (en) | Micro rna liver cancer markers and uses thereof | |
| GB2601600A (en) | Apparatus, kits and methods for predicting the development of sepsis | |
| CN116068193B (zh) | 结核病分子标志物组合及其用途 | |
| TWI626314B (zh) | 評估罹患大腸直腸癌風險的方法 | |
| EP4361289A1 (en) | Detection of gene expression pattern specific to pancreatic cancer, and detection of pancreatic cancer through combination with measurement of ca19-9 | |
| US20250163514A1 (en) | Epigenetic biomarkers for the diagnosis of thyroid cancer | |
| KR20250159710A (ko) | 암 진단 모델의 개발 방법 및 암 검출 방법 개발에서의 이의 용도 | |
| TWI718474B (zh) | 評估個體罹患泌尿上皮癌之風險的方法及其套組 | |
| EP4217508A1 (en) | Apparatus, kits and methods for predicting the development of sepsis | |
| JP5861048B1 (ja) | 遺伝子発現解析による大腸癌の検出 |